Original Article

You have full text access to this OnlineOpen article

Vinblastine, bleomycin, and methotrexate chemotherapy plus irradiation for patients with early-stage, favorable Hodgkin lymphoma

The experience of the Gruppo Italiano Studio Linfomi

  1. Paolo G. Gobbi M.D.1,†,*,
  2. Chiara Broglia M.D.1,
  3. Francesco Merli M.D.2,
  4. Matteo Dell'Olio M.D.3,
  5. Caterina Stelitano M.D.4,
  6. Emilio Iannitto M.D.5,
  7. Massimo Federico M.D.6,
  8. Raffaella Bertè M.D.7,
  9. Dimitri Luisi M.D.8,
  10. Stefano Molica M.D.9,
  11. Carla Cavalli M.D.10,
  12. Laura Dezza M.D.11,
  13. Edoardo Ascari M.D.1

Article first published online: 3 NOV 2003

DOI: 10.1002/cncr.11807

Issue

Cancer

Cancer

Volume 98, Issue 11, pages 2393–2401, 1 December 2003

Additional Information

How to Cite

Gobbi, P. G., Broglia, C., Merli, F., Dell'Olio, M., Stelitano, C., Iannitto, E., Federico, M., Bertè, R., Luisi, D., Molica, S., Cavalli, C., Dezza, L. and Ascari, E. (2003), Vinblastine, bleomycin, and methotrexate chemotherapy plus irradiation for patients with early-stage, favorable Hodgkin lymphoma. Cancer, 98: 2393–2401. doi: 10.1002/cncr.11807

Author Information

  1. 1

    Medicina Interna e Oncologia Medica, Università di Pavia, Istituto di Ricovero e Cura a Carattere Scientifico Policlinico San Matteo, Pavia, Italy

  2. 2

    Ematologia, Arcispedale Santa Maria Nuova, Reggio Emilia, Italy

  3. 3

    Ematologia, Istituto di Ricovero e Cura a Carattere Scientifico “Casa Sollievo della Sofferenza,” San Giovanni Rotondo, Foggia, Italy

  4. 4

    Ematologia, Ospedali Riuniti, Reggio Calabria, Italy

  5. 5

    Ematologia con Trapianto di Midollo, Università di Palermo, Palermo, Italy

  6. 6

    Oncologia Medica, Università di Modena. Modena, Italy

  7. 7

    Sezione di Ematologia, Divisione di Medicina Interna, Ospedale Civile, Piacenza, Italy

  8. 8

    Oncologia, Ospedale Santo Spirito, Pescara, Italy

  9. 9

    Oncologia, Ospedale A. Pugliese, Catanzaro, Italy

  10. 10

    Medicina Generale, Ospedale Civile, Vigevano, Pavia, Italy

  11. 11

    Medicina II, Ospedale Predabissi, Vizzolo-Predabissi, Italy

  1. †

    Fax: (011) 39 0382 526223

*Clinica Medica e Oncologia Medica, Università di Pavia, Istituto di Ricovero e Cura a Carattere Scientifico Policlinico S. Matteo, P. le Golgi no. 2, 27100 Pavia, Italy

Publication History

  1. Issue published online: 17 NOV 2003
  2. Article first published online: 3 NOV 2003
  3. Manuscript Accepted: 22 AUG 2003
  4. Manuscript Revised: 18 AUG 2003
  5. Manuscript Received: 3 JUN 2003

Funded by

  • Ministero dell'Università (Rome, Italy)
  • Adolfo Ferrata e Edoardo Storti Foundation (Pavia, Italy)

SEARCH

SEARCH BY CITATION

ARTICLE TOOLS

View Full Article (HTML) Get PDF (110K)

REFERENCES

  • 1
    Aisenberg AC. Problems in Hodgkin's disease management. Blood. 1999; 93: 761–779.
  • 2
    Horning SJ, Hoppe RT, Hancock SL, et al. Vinblastine, bleomycin, and methotrexate: an effective adjuvant chemotherapy in favorable Hodgkin's disease. J Clin Oncol. 1988; 6: 1822–1831.
  • 3
    Nordijk E, Carde P, Mandard AM, et al. Preliminary results of the EORTC-GPMC controlled clinical trial H7 in early stage Hodgkin's disease. EORTC Lymphoma Cooperative Group. Group Pierre-et-Marie-Curie. Ann Oncol. 1994; 5(Suppl 2): 523–529.
  • 4
    Moody AM, Pratt J, Hudson GV, et al. British National Lymphoma Investigation: pilot studies of neoadjuvant chemotherapy in clinical Stage IA and IIA Hodgkin's disease. Clin Oncol (R Coll Radiol). 2001; 13: 262–268.
  • 5
    Gobbi PG, Pieresca C, Frassoldati A, et al. Vinblastine, bleomycin, and methotrexate chemotherapy plus extended-field radiotherapy in early, favorably presenting, clinically staged Hodgkin's patients: the Gruppo Italiano per lo Studio dei Linfomi experience. J Clin Oncol. 1996; 14: 527–533.
  • 6
    Lister TA, Crowther D, Sutcliff SB, et al. Report of a committee convened to discuss the evaluation and staging of patients with Hodgkin's disease. J Clin Oncol. 1989; 7: 1630–1636.
  • 7
    Hryniuk WM. Average relative dose intensity and the impact on design of clinical trials. Semin Oncol. 1987; 14: 65–74.
  • 8
    DeVita VT Jr., Hubbard SM, Longo DL. The chemotherapy of lymphoma: looking back, moving forward—The Richard and Hinda Rosenthal Foundation Award Lecture. Cancer Res. 1987; 47: 5810–5824.
  • 9
    Oken MM, Creech RH, Tormey DC, et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol. 1982; 5: 129–137.
  • 10
    Armitage P, Berry G. Statistical methods in medical research (2nd edition). Oxford: Blackwell Scientific, 1987: 296–357.
  • 11
    Dixon DO, McLauglin P, Hagemeister FB, et al. Reporting outcomes in Hodgkin's disease and lymphoma. J Clin Oncol. 1987; 5: 1670–1672.
  • 12
    Carde P. Should poor risk patients with Hodgkin's disease be sorted out for intensive treatments? Leuk Lymphoma. 1995; 15: 31–40.
  • 13
    Longo DL, Duffey PL, Young RC, et al. Conventional-dose salvage combination chemotherapy in patients relapsing with Hodgkin's disease after combination chemotherapy: the low probability for cure. J Clin Oncol. 1992; 10: 210–218.
  • 14
    Kaplan EL, Meier P. Nonparametric estimation from incomplete observation. J Am Stat Assoc. 1958; 53: 457–481.
  • 15
    Bates NP, Williams MV, Bessell EM, et al. Efficacy and toxicity of vinblastine, bleomycin, and methotrexate with involved-field radiotherapy in clinical Stage IA and IIA Hodgkin's disease: a British National Lymphoma Investigation pilot study. J Clin Oncol. 1994; 12: 288–296.
  • 16
    Horning SJ, Hoppe RT, Mason J, et al. Stanford-Kaiser Permanente G1 study for clinical Stage I to IIA Hodgkin's disease: subtotal lymphoid irradiation versus vinblastine, methotrexate and bleomycin chemotherapy and regional irradiation. J Clin Oncol. 1997; 15: 1736–1744.
  • 17
    Zinzani PL, Magagnoli M, Bendandi M, et al. Efficacy of the VBM regimen in the treatment of elderly patients with Hodgkin's disease. Haematologica. 2000; 85: 729–732.
  • 18
    Martinelli G, Cocorocchio E, Peccatori F, et al. Abstract CO-024 [abstract]. Haematologica. 2001; 86(Suppl 10): 19.
  • 19
    Kun LE, DeVita VT Jr., Young RC, et al. Treatment of Hodgkin's disease using intensive chemotherapy followed by irradiation. Int J Radiat Oncol Biol Phys. 1976; 1: 619–626.
  • 20
    Bonadonna G, Zucali R, De Lena M,et al. Combined chemotherapy (MOPP or ABVD)-radiotherapy approach in advanced Hodgkin's disease. Cancer Treat Rep. 1977; 61: 769–777.
  • 21
    Kaplan HS, Rosenberg SA. The management of Hodgkin's disease. Cancer. 1975; 36: 796–803.
    Direct Link:
  • 22
    Ginsberg SJ, Comis R. The pulmonary toxicity of antineoplastic agents. Semin Oncol. 1982; 9: 34–42.
View Full Article (HTML) Get PDF (110K)